MeiraGTx Holdings plc
Research MeiraGTx Holdings plc (MGTX) on Bullrun: market cap USD 1.41B, P/E 21.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMGTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.41B
- P/E21.1
- Financial periodQ1 2026
- RevenueUSD 293.00K
- Net income-USD 46.31M
- Free cash flowUSD 3.50M
- Gross margin32.4%
Valuation Snapshot
latest market cap is USD 1.41B; P/E is 21.1.
Peer valuation comparison
Latest P/E is 21.14x versus a Healthcare sector median of 24.46x (13.6% below).
Latest P/E is 21.14x versus a United States median of 24.87x (15.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 81.39M | -USD 114.20M | -USD 50.19M | 94.0% | -1.42 | USD 65.93M | USD 88.69M | -USD 5.79M |
| FY2024 | USD 33.28M | -USD 147.79M | -USD 109.45M | 28.5% | -2.12 | USD 103.66M | USD 84.80M | USD 67.83M |
| FY2023 | USD 14.02M | -USD 84.03M | -USD 125.54M | n/a | -1.49 | USD 129.57M | USD 89.26M | USD 138.18M |
| FY2022 | USD 15.92M | -USD 129.62M | -USD 118.06M | n/a | -2.87 | USD 115.52M | USD 22.70M | USD 117.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.41B | 21.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 644.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 477.44M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 446.45M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 316.07M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.06B | n/a | n/a | n/a |
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MeiraGTx Holdings plc's market cap?
MeiraGTx Holdings plc's market capitalization is USD 1.41B.
What is MeiraGTx Holdings plc's P/E ratio?
MeiraGTx Holdings plc's price-to-earnings (P/E) ratio is 21.1.
What does MeiraGTx Holdings plc do?
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.